Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Gary Mohilner who wrote (3801)	1/17/2001 8:31:38 PM
From: RJMC	Read Replies (1) \| Respond to of 5665

It is the calm before the storm. Looks like everyone is biding their time until some news comes out. The efficacy milestone would be absolutely outstanding news! As it is, seems like we might finish out the month quietly. The bottom of the cup is starting to form on the chart. Who knows where the stock price will pole vault to during the next growth session. If the efficacy milestone is met during the next couple months, seems like the price should handily reach the triple digit mark sometime this year. I think the analysts were being very conservative when they set targets of around $50-55 for this year. I certainly haven't seen any of them back down. I'm going to try to accumulate a few more shares before May. It certainly isn't as easy to accumulate as it was when I first started buying this stock. Looks like the biotech stocks are getting a bit oversold. They may start tracking up again fairly soon. Some good news anywhere in the biotech sector (maybe even from IMGN) might be the catalyst that starts driving biotech up again. Looks like the market has finally settled from its downward bear run. Bob M.